CAMBRIDGE, Mass. and GAITHERSBURG, Md., Sept. 17, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted IPI-504 orphan drug designation for the treatment of gastrointestinal stromal tumors (GIST). IPI-504, the companies' heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated in two separate multi-center clinical trials in patients with GIST and other soft tissue sarcomas (STS), and in patients with non-small cell lung cancer.
